Ascendis Pharma gets EU approval for new drug
- CHMP recommends marketing authorization for TransCon CNP in EU
- EMA to review data to maintain orphan designation
- Expected EC decision in Q4 2026
ASND
Ascendis Pharma A/S SEC filings
Every EDGAR filing for Ascendis Pharma A/S (ASND), newest first, with AI summaries and stories.
- Ticker
- ASND
- CIK
- 1612042
- Latest filing
- 2d
Filings
6-KAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE Ascendis Pharma grants 35,890 warrants
- Warrants granted to employees on 2026-10-13
- Exercise price of $223.21 per share
- 25% vest after 1 year, 75% over 3 years
6-KAscendis Pharma A/SASNDLIVE 4Ascendis Pharma A/SASNDLIVE Jean Jacques Bienaime, insider filing for ASND
Jean Jacques Bienaime, reporting
6-KAscendis Pharma A/SASNDLIVE 4Ascendis Pharma A/SASNDLIVE Mads Bodenhoff, insider filing for ASND
Mads Bodenhoff, reporting
6-KAscendis Pharma A/SASNDLIVE 144Ascendis Pharma A/SASNDLIVE Mads Bodenhoff, planned sale of ASND shares
Mads Bodenhoff, reporting
4Ascendis Pharma A/SASNDLIVE Lars Holtug, insider filing for ASND
Lars Holtug, reporting
144Ascendis Pharma A/SASNDLIVE Lars Holtug, planned sale of ASND shares
Lars Holtug, reporting
6-KAscendis Pharma A/SASNDLIVE 4Ascendis Pharma A/SASNDLIVE Jean Jacques Bienaime, insider filing for ASND
Jean Jacques Bienaime, reporting
SCHEDULE 13G/AAscendis Pharma A/SASNDLIVE Ownership stake disclosure by Artisan Partners Limited Partnership (amended)
Artisan Partners Limited Partnership, filed by
6-KAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE 4Ascendis Pharma A/SASNDLIVE Scott Thomas Smith, insider filing for ASND
Scott Thomas Smith, reporting
4Ascendis Pharma A/SASNDLIVE 3 insider filings
Jean Jacques Bienaime, insider filing for ASND
Show all 3
- 4Insider filing for ASND
- 4Insider filing for ASND
- 3/ANew insider at ASND (amended)
Jean Jacques Bienaime, reporting
4Ascendis Pharma A/SASNDLIVE Jean Jacques Bienaime, insider filing for ASND
Jean Jacques Bienaime, reporting
SDAscendis Pharma A/SASNDLIVE SCHEDULE 13G/AAscendis Pharma A/SASNDLIVE Ownership stake disclosure by JANUS HENDERSON GROUP PLC (amended)
JANUS HENDERSON GROUP PLC, filed by
SCHEDULE 13G/AAscendis Pharma A/SASNDLIVE Ownership stake disclosure by Capital International Investors (amended)
Capital International Investors, filed by
6-KAscendis Pharma A/SASNDLIVE 4Ascendis Pharma A/SASNDLIVE Flemming Steen Jensen, insider filing for ASND
Flemming Steen Jensen, reporting
144Ascendis Pharma A/SASNDLIVE Flemming Steen Jensen, planned sale of ASND shares
Flemming Steen Jensen, reporting
SCHEDULE 13G/AAscendis Pharma A/SASNDLIVE 2 13G filings
Ownership stake disclosure by T. Rowe Price Investment Management, Inc. (amended)
Show all 2
- SCHEDULE 13G/AOwnership stake disclosure (amended)
- SCHEDULE 13GOwnership stake disclosure
T. Rowe Price Investment Management, Inc., filed by
6-KAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE SCHEDULE 13G/AAscendis Pharma A/SASNDLIVE Ownership stake disclosure by FMR LLC (amended)
FMR LLC, filed by
6-KAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE 8-A12B/AAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE 3Ascendis Pharma A/SASNDLIVE Jean Jacques Bienaime, new insider at ASND
Jean Jacques Bienaime, reporting
6-KAscendis Pharma A/SASNDLIVE 6-KAscendis Pharma A/SASNDLIVE